ArticleALTEX2020
The exposome - a new approach for risk assessment.
Article in ALTEX, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 82 citations in OpenAlex.
- Leveraging Artificial Intelligence in Allergy, Asthma, and Immunology With Environmental Exposures.Allergy · 2026Review
- Artificial Intelligence-Powered One Health: A Predictive Framework for Managing Persistent Chemical Threats across Human, Animal, and Environmental Systems.Global challenges (Hoboken, NJ) · 2026Review
- Charting exposomethics: a roadmap for the ethical foundations of the human exposome project.Human genomics · 2026Review
- The data substrate of exposome intelligence: an interoperability profile for untargeted metabolomics.Frontiers in artificial intelligence · 2026Article
- AI snake oil? A risk/benefit analysis for toxicology.Frontiers in artificial intelligence · 2026Article
- All things are active … new approach methods for excipient safety.Frontiers in pharmacology · 2026Article
- Microphysiological systems as a pillar of the Human Exposome Project.The Journal of biological chemistry · 2025Review
- Article
- Cumulative risk assessment as the pathway to public health protection for behavioral neurotoxicity.Neurotoxicology · 2025Review
- Advancing translational exposomics: bridging genome, exposome and personalized medicine.Human genomics · 2025Review
- The Impact of the Exposome on Alzheimer's Disease: The Influence of Nutrition.International journal of molecular sciences · 2025Review
- AI redefines mass spectrometry chemicals identification: retention time prediction in metabolomics and for a Human Exposome Project.Frontiers in public health · 2025Review
- Mechanistic read-across comes of age: a comparative appraisal of EFSA 2025 guidance, ECHA's RAAF, and good read-across practice.Frontiers in toxicology · 2025Review
- Article
- Reconceptualizing and Defining Exposomics within Environmental Health: Expanding the Scope of Health Research.Environmental health perspectives · 2024Article
- Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends.Metabolites · 2024Review
- AI and ML-based risk assessment of chemicals: predicting carcinogenic risk from chemical-induced genomic instability.Frontiers in toxicology · 2024Review
- Global challenges in aging: insights from comparative biology and one health.Frontiers in toxicology · 2024Review
- Integrating the exposome and one health approach to national health surveillance: an opportunity for Latin American countries in health preventive management.Frontiers in public health · 2024Article
- The contribution of the exposome to the burden of cardiovascular disease.Nature reviews. Cardiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Complementing the human genome with an exposome reflects the increasingly obvious impact of environmental exposure, which far exceeds the role of genetics, on human health. Considering the complexity of exposures and, in addition, the reactions of the body to exposures - i.e., the exposome - reverses classical exposure science where the precise measurement of single or few exposures is associated with specific health or environmental effects. The complete description of an individual's exposome is impossible; even less so is that of a population. We can, however, cast a wider net by foregoing some rigor in assessment and compensating with the statistical power of rich datasets. The advent of omics technologies enables a relatively cheap, high-content description of the biological effects of substances, especially in tissues and biofluids. They can be combined with many other rich data-streams, creating big data of exposure and effect. Computational methods increasingly allow data integration, discerning the signal from the noise and formulating hypotheses of exposure-effect relationships. These can be followed up in a targeted way. With a better exposure element in the risk equation, exposomics - new kid on the block of risk assessment - promises to identify novel exposure (interactions) and health/environment effect associations. This may also create opportunities to prioritize the more relevant chemicals for risk assessment, thereby lowering the burden on hazard assessment in an expo-sure-driven approach. Technological developments and synergies between approaches, quality assurance (ultimately as Good Exposome Practices), and the integration of mechanistic thinking will advance this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.